Summary
Becton, Dickinson and Company (BDX) has announced significant financing activities through multiple debt offerings, including €1 billion in 3.828% Notes due 2032, €800 million in 4.029% Notes due 2036 issued by its subsidiary Becton Dickinson Euro Finance S.à r.l. (guaranteed by BDX), and $600 million in 5.081% Notes due 2029. The primary purpose of these offerings is to fund the cash consideration for the anticipated acquisition of Edwards Lifesciences Corporation's Critical Care business, along with associated fees, expenses, and general corporate purposes. While these offerings are not contingent on the acquisition's completion, their proceeds are earmarked for this strategic move.
Key Highlights
- 1BDX has raised a total of approximately €1.8 billion and $600 million through separate Euro and USD denominated notes offerings.
- 2The proceeds from these debt issuances are intended to finance the acquisition of Edwards Lifesciences' Critical Care business.
- 3The Euro-denominated notes include €1 billion of 3.828% Notes due 2032 (issued by BDX) and €800 million of 4.029% Notes due 2036 (issued by a subsidiary and guaranteed by BDX).
- 4The USD-denominated notes consist of $600 million of 5.081% Notes due 2029.
- 5The debt offerings are not conditioned on the consummation of the acquisition, though there is no assurance the acquisition will be completed.
- 6Specific redemption and default provisions are detailed for each note series, including options for early redemption under certain conditions (e.g., tax law changes, change of control) and mandatory redemption if the acquisition does not proceed.
- 7The subsidiary's notes carry a special mandatory redemption provision if the acquisition is not completed by a specified date (June 3, 2025, or later agreed date) or if BDX decides not to pursue it.